MedTrace Logo

A Phase 1 Study of TDM-180935 Following Topical Administration in Healthy Male Subjects

NCT05525468 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2023-11-18

No results posted yet for this study

Summary

Multi-center, randomized, double-blind, vehicle-controlled, parallel group, dose escalation study of TDM-180935 following topical administration in healthy male subjects, 18 to 55 years old

Conditions

  • Healthy

Interventions

DRUG

TDM-180935

TDM-180935 topical ointment

DRUG

Placebo

Placebo for TDM-180935 topical ointment

Sponsors & Collaborators

  • Therapeutics, Inc.

    collaborator INDUSTRY

  • Technoderma Medicines Inc.

    lead INDUSTRY

Principal Investigators

  • Daniel J. Piacquadio, M.D. · Therapeutics Incorporated

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-02-08
Primary Completion
2023-08-18
Completion
2023-10-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05525468 on ClinicalTrials.gov